Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 2/20 | 0.37 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.37 |
| ▸ | PYGL | P06737 | 2/20 | 0.33 |
| ▸ | LMNA | P02545 | 3/20 | 0.32 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.32 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.32 |
| ▸ | HTR1A | P08908 | 1/20 | 0.32 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.32 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.32 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.32 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.32 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.32 |
| ▸ | AOC3 | Q16853 | 1/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | RAPGEF4 | Q8WZA2 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.30 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.30 |
| ▸ | ADRB3 | P13945 | 1/20 | 0.30 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.30 |
| ▸ | GABRB1 | P18505 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25857242 | 0.79 | ABCB11 (0.37) | ADRB2RAPGEF4GABRA1GABRB1 | |
| SCHEMBL17025364 | 0.78 | GABRA1 (0.37) | TSHRRAPGEF4GABRA1GABRB1 | |
| SCHEMBL17025386 | 0.78 | GABRA1 (0.37) | TSHRRAPGEF4GABRA1GABRB1 | |
| SCHEMBL19827528 | 0.78 | SCN4A (0.36) | ADRB2 | |
| SCHEMBL17132529 | 0.76 | PPARG (0.33) | — | |
| SCHEMBL18713913 | 0.74 | RAPGEF4 (0.36) | TSHRRAPGEF4 | |
| SCHEMBL10417662 | 0.73 | LMNA (0.30) | TSHRLMNA | |
| SCHEMBL6367023 | 0.73 | POLB (0.42) | SMN1; SMN2 | |
| SCHEMBL6367016 | 0.73 | POLB (0.42) | SMN1; SMN2 | |
| SCHEMBL6367015 | 0.73 | POLB (0.42) | SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7763597-B2 | Salts | ASTRAZENECA AB (SE) | 2010-07-27 | — | — | US | disclosed |
| US-20080269176-A1 | New Salts | ASTRAZENECA AB (SE) | 2008-10-30 | — | — | US | disclosed |
| US-7273858-B2 | Sulfonic acid salts of 2-(p-(alkoxyamidino)benzylaminocarbonyl)azetidin-1-yl 3-chloro-5-(fluorinated alkoxy)-alpha-hydroxybenzyl ketone; competitive inhibitors of trypsin-like proteases, such as thrombin; anticoagulants | ASTRAZENECA AB (SE) | 2007-09-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080269176-A1 | New Salts | PRSS1, PRSS2, CTRL | TSHR 489/4885CYP3A4 195/4885PYGL 567/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.